Genetics and Drug discovery
Novo Nordisk Research Centre Oxford (NNRCO) is an innovative target discovery unit with a focus on identifying novel, game-changing therapies for patients with type 2 diabetes and cardiometabolic diseases.

They employ advanced computational biology, state-of-the-art discovery screening technologies, genetics and human-centric cell systems to dissect pathophysiology and identify novel drug targets. The site is a fusion of the best of academia, biotech and big pharma in order to realize cutting-edge biology and start a target’s journey from bench to bedside.

NNRCO operates at the boundaries of frontier science with a mandate to find dynamic, agile and distinctive new ways of working to diversify the company’s pipeline with disruptive medicines.
Date: 7 September 2023, 12:00
Venue: IMS-Tetsuya Nakamura Building, Roosevelt Dr, Headington OX3 7TY
Venue Details: Large ground floor seminar room
Speaker: Jo Howson (Novo Nordisk)
Organising department: Medical Sciences Division
Organisers: Eneida Parizotto (University of Oxford), Sheena Lee (MSD Business Partnerships Office), Medical Sciences Division Business Partnerships Office (University of Oxford)
Organiser contact email address: sheena.lee@medsci.ox.ac.uk
Host: Eneida Parizotto (University of Oxford)
Part of: Industry Insight Seminar Series
Booking required?: Required
Booking url: https://www.eventbrite.co.uk/e/industry-insights-seminar-series-tickets-131313804123
Cost: None
Audience: Members of the University of Oxford and the UK Biotech/Pharma industry
Editor: Sheena Lee